BARCLAYS
7.9.2022 09:01:53 CEST | Business Wire | Press release
Barclays has appointed Daniel Hanna as Global Head of Sustainable Finance for the Corporate and Investment Bank with the responsibility for creating a market-leading center of excellence for sustainable finance. He will be based in London and joins the Corporate and Investment Bank’s Management Committee.
“The center of excellence will bring together the power of our 'One Barclays' approach to deliver a fuller suite of products, solutions, and expertise to clients as they navigate the transition to a low-carbon economy,” said Paul Compton, Global Head of Corporate and Investment Bank and President, Barclays Bank Plc. “He will partner closely with the Sustainable Capital Markets, Sustainable and Impact Banking, and the Sustainable Product Group teams, as well as with Barclays’ Sustainability and ESG team to ensure connectivity with Barclays’ broader firm-wide efforts.”
“We are focused on the delivery of our climate strategy, including capturing new opportunities to deepen client relationships and create new growth for Barclays’ businesses,” said Sasha Wiggins, Barclays’ Group Head of Public Policy and Corporate Responsibility. “Whilst we are already using our expertise across our Corporate and Investment Bank to help clients manage this period of extraordinary change, Daniel’s appointment gives us a powerful focus to create a real point of difference with clients.”
Mr. Hanna joins Barclays from Standard Chartered, where he was most recently Global Head of Sustainable Finance.
“Barclays was one of the first banks to commit to net zero by 2050 and has a fantastic track record of innovation in green and sustainable finance,” said Mr. Hanna. “As the world deals with the impact of high energy prices and climate change, Barclays has a strong platform to help channel capital to the new technologies, and companies, that can help economies decarbonize and drive sustainable growth.”
The transition to a low carbon economy is today’s defining opportunity for innovation and growth - supporting clients in their efforts to decarbonise and adapt their business models is a strategic priority at Barclays. There is a significant opportunity for Barclays to play a leading role in helping to meet the demand for financing to support the energy transition, channelling investment into new green technologies and low-carbon infrastructure projects. Barclays has already facilitated £74bn of green financing, including landmark projects such as supporting the UK Government to issue their first green bond, which will finance projects such as offshore wind and schemes to decarbonise homes and buildings. To find out more about Barclays’ approach to climate change, please visit our website.
About Barclays
Barclays is a British universal bank. We are diversified by business, by different types of customer and client, and geography. Our businesses include consumer banking and payments operations around the world, as well as a top-tier, full service, global corporate and investment bank, all of which are supported by our service company which provides technology, operations and functional services across the Barclays Group. For further information about Barclays, please visit our website home.barclays.
About Barclays Corporate and Investment Bank
Barclays is a consumer and wholesale bank, supporting individuals and small businesses through our consumer banking services, and larger businesses and institutions through our corporate and investment banking services. Our Corporate and Investment Bank is comprised of the Investment Banking, International Corporate Banking, Global Markets and Research businesses; it provides money managers, financial institutions, governments, supranational organisations and corporate clients with services and advice for their funding, financing, strategic and risk management needs. For further information about Barclays Corporate and Investment Bank, please visit our website www.cib.barclays.
About Barclays Commitment to Address Climate Change
In March 2020, Barclays announced an ambition to be a net zero bank by 2050, becoming one of the first banks to do so. Barclays is working to achieve net zero operations, investing in the continued decarbonisation of our operations, and in the development of a net zero pathway for the emissions from our supply chain. Barclays is also committed to aligning its financing with the goals and timelines of the Paris Agreement and to providing the green and sustainable finance required to transform the economies it serves.
About Barclays’ Sustainable Capital Markets (SCM) Team
Barclays’ Sustainable Capital Markets (SCM) team offers a broad range of ESG capital market product types and delivers across multiple client segments to help clients finance their sustainability journeys and formalise their sustainability commitments.
About Barclays’ Sustainable and Impact Banking (SIB) Team
Barclays’ Sustainable and Impact Banking (SIB) team advises and raises capital for emerging growth companies that are addressing ESG issues, as well as for existing clients navigating their energy transitions.
About Barclays’ Sustainable Product Group (SPG) Team
Barclays’ Sustainable Product Group (SPG) team offers a set of green products based on Barclays Green Finance Framework, including Green Innovation Finance, Green Loans, Green Asset Finance, Green Trade Finance, Green Infrastructure and Project Finance, and Green Deposits.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220907005147/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom